Clinical Trials Logo
  1. Home
  2. Hematologic Cancer
  3. NCT03955276

An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme) — I-PREDICT Heme  

Hematologic Cancer Clinical Trial

Official title:
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies and Poor Prognoses (I-PREDICT Heme)

Clinical Trial Summary

The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement Amendments (CLIA) certified comprehensive genomic analysis. The molecular mutation profile will then be matched to existing, FDA-approved, targeted agents or to existing clinical trials using investigational agents for treatment of patients with incurable hematologic malignancies for whom no effective standard therapy exists or who have either exhausted or are intolerant of standard options.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03955276
Study type Observational
Source University of California, San Diego
Contact
Status Terminated
Phase
Start date February 7, 2019
Completion date January 13, 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT04966156 - Cancer Rehab Program for Allogenic Bone and Marrow Transplant Patients - CaRE-4-alloBMT N/A
Recruiting NCT05942885 - Hypnosis: a Path to Appeasement N/A
Recruiting NCT05715047 - Intervention for Fatigue in HCT Recipients N/A
Recruiting NCT05142033 - Avera Cancer Sequencing and Analytics Protocol (ASAP)
Completed NCT06053918 - Research-Action in Hematology From Hospitalization to Home
Recruiting NCT05175508 - Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Phase 2/Phase 3
Not yet recruiting NCT04822974 - TORQUETENOVIRUS IN CAR-T THERAPY: PREDICTION OF THE CRS N/A
Not yet recruiting NCT06279585 - Physical Therapy in Patients Undergoing Allo-HSCT With cGVHD N/A
Recruiting NCT05753501 - Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies Phase 1
Recruiting NCT05481502 - An Exploratory Study to Evaluate Immune Determinants of the Response to Adoptive Cell Therapy (ACT) in Solid and Hematologic Tumors N/A
Not yet recruiting NCT04412135 - The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality
Not yet recruiting NCT06377059 - Early Detection of Complications During Immunotherapy for Haematological Malignancy N/A
Completed NCT04235153 - CAncer, NUtrition and Taste - Validation of the CANUT-QVA Questionnaire on Eating Habits in Cancer Patients
Recruiting NCT05626764 - QUALITOP - Monitoring Multidimensional Aspects of QUAlity of Life After Cancer ImmunoTherapy, an Open Smart Digital Platform for Personalized Prevention and Patient Management
Active, not recruiting NCT04035447 - Symptom Management for YA Cancer Survivors N/A
Not yet recruiting NCT05602168 - Collection of Sequential Samples From Patients With Malignant Myeloid Hemopathy for the Study of Treatment Resistance N/A
Recruiting NCT03091933 - Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) Phase 1/Phase 2
Withdrawn NCT01792882 - Prospective Collection of Surplus Surgical Tumor Tissues and Pre-surgical Blood Samples
Recruiting NCT05493800 - Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT Phase 2
Active, not recruiting NCT05690230 - Improving Patient Experience: BMBA N/A